Docoh
Loading...

RGBP Regen BioPharma

Filed: 5 Nov 21, 10:01am

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 12, 2021

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada45-5192997
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

 

Commission File No. 333-191725  

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

(619) 722 5505

(Issuer’s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class Trading Symbol(s) Name of each exchange on which registered
  None  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 1 

 

Item 8.01 Other Events.

 

Between July 16, 2021 and November 4, 2021 Regen Biopharma, Inc. (the “Company”) has satisfied $967,830 of principal indebtedness on convertible notes payable and $539,392 in fees, penalties and interest accrued but unpaid on convertible notes payable through the issuance of 706,451,543 of the Company’s common shares, 23,720,548 of the Company’s Series A Preferred shares and payment to noteholders of $218,529 in cash. As of June 30, 2021 the Company had convertible notes payable with an outstanding principal balance of $2,364,075 and as of November 4, 2021 the Company had convertible notes payable with an outstanding principal balance of $1,396,245.

 

 2 

 

 


SIGNATURE 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 REGEN BIOPHARMA, INC.
  
Dated: November 4, 2021By: /s/ David Koos
 David Koos
 Chief Executive Officer

 

 3